Company Overview and News
I am predicting another monthly dividend increase to $0.195 per month to be announced before the company reports earnings on August 2, 2018, for the reasons discussed in this article.
CLA MCQ TCAP KAP MCV PFLT OSLE CGBD GLADO HTGZ KCAP GLAD ABDC MSCA TSLX TCCB CPTA TCCA MCC ARCC HCAPL GBDC FDUS MAIN TCC TCPC HTGX NMFC HTGY OCSI ARU OCSL MSCA.CL MCX HCAP SUNS HTGC
Ares Capital Corp. is a business development company that seeks investment opportunities in middle market companies with EBITDA of $10 - $250 million located in the US. The fund targets companies operating across a broad range of sectors, including healthcare services, business services, education, energy, financial services, consumer products, restaurants & food services, containers & packaging, automotive services, manufacturing, retail, aerospace & defense and chemicals.
ARU ARCC AFC
The performance of 59 securities, which were selected by SA contributors for their high-yield portfolios in 2014, are identified and analyzed for the period May 2014 to July 2018.
AIY AINV ARI PCI RSO.PRBCL NYMTO HTF KAP OSLE NYMTP KCAP FGB AI AI.PRB CMO TWO SDRL HTFA AGNC AIW TWO.PRA SLRA TWO.PRB RSO TWO.PRC WMC AIC NLY.PRECL AIB TCRD PSEC NMFC CYS AIF TSLF MCX SCQ XAN PBB MITT.PRB MITT.PRA RSO.PRA RSO.PRB RSO.PRC SCA RSO.PRACL MCQ HRZN CHW OXLCO MCV OXLCN STWD.WI MITT SCM HTGZ MFA.PRA SLRC MFA.PRB CYS.PRA CYS.PRB BIT MCC TCRX ARCC ARI.PRA GBDC CLMT ARI.PRC MFO DX NLY NLY.PRA TCPC NLY.PRD NLY.PRE TCRZ HTGX OXLC HTGY NLY.PRC ARU OCSL EFC NLY.PRF NLY.PRG MFA DX.PRB NYMT HTGC DX.PRA STWD
TCPC is likely under-priced for the reasons discussed in this article, trading under book value, RSI of 38, and offering a well-supported 10% dividend yield.
AIY AINV CLA MCQ TCAP KAP MCV PFLT OSLE CGBD GLADO HTGZ KCAP GLAD ABDC MSCA TSLX TCCB CPTA TCCA MCC ARCC HCAPL GBDC FDUS MAIN TCC TCPC AIB HTGX NMFC HTGY CNO OCSI ARU OCSL MSCA.CL MCX HCAP SUNS HTGC
Ares Capital Corporation’s (ARCC - Free Report) board of directors approved to lower the minimum asset coverage ratio to 150% from 200%, as per the amendment in the Investment Company Act of 1940 by the Small Business Credit Availability Act. The amendment is subject to certain approval, timing and disclosure requirements. The effective date, from which the ratio will be lowered, is Jun 21, 2019. Notably, the debt/equity ratio ceiling of 1.
CMFN ARCC EPC KMI.WS SM ARES.PRA WHFBL ARES WHF ARU SLRC KMI.PRA KMI ZAGG KMR SLRA CVB KMRFZ
My primary concern is the amount of investments that “require close monitoring”, which has increased from 6% to 21% of the portfolio over the last two quarters.
CLA MCQ TCAP KAP MCV PFLT OSLE MM CGBD GLADO HTGZ KCAP GLAD ABDC MSCA TSLX TCCB CPTA TCCA FDMCF MCC ARCC HCAPL GBDC MMCC EVEP FSIC FDUS MAIN TCC TCPC HTGX NMFC HTGY OCSI ARU OCSL MSCA.CL MCX HCAP SUNS HTGC
There's a way we can give ourselves a raise, even when a company doesn't give us one.
SOJA GEO EPR.PRG O.PRF CTL LTC BATS 4162 OPRF SUI.PRA VZA SUI MSCA HMNY ED MO GOV SO ARCC O MAIN RMR GOVNI ARU MSCA.CL VGR SIR ROKU CLDT VZ WPC OHI
Two of PSEC's largest investments will likely have upcoming writedowns, especially given that company has a fiscal year-end June 30, requiring a full audit.
CLA MCQ TCAP KAP PNNT MCV PFLT OSLE CGBD GLADO HTGZ KCAP GLAD ABDC MSCA TSLX TCCB CPTA TCCA MCC ARCC HCAPL GBDC FDUS MAIN TCC TCPC PSEC HTGX NMFC HTGY OCSI ARU OCSL MSCA.CL MCX HCAP SUNS HTGC PBB PNTA
Part 2 of this article discusses two topics/trends impacting PSEC’s future dividend and NAV sustainability (forward-looking metrics).
ACSF AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC MSCA TSLX NEWT SLRA MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ ARU OCSI MSCA.CL OCSL MCX TRI NEWTL PBB
The Fed Chair is very sanguine on the outlook for the U.S. economy going forward, supporting his intent to proffer two more raises this year.
SOJA GEO EPR.PRG O.PRF CTL LTC BATS 4162 OPRF SUI.PRA VZA SUI MSCA HMNY ED MO GOV SO ARCC O MAIN RMR GOVNI ARU MSCA.CL VGR ROKU CLDT VZ WPC OHI
Following continued requests from readers, this article first performs a FMV investing rating analysis on TSLX’s portfolio companies over the prior four quarters.
ACSF AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC RXNRP REXXQ MSCA TSLX NEWT SLRA MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX REXX JIVE NEWTL PBB
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to ARU / Ares Capital Corp. 5.875% Bond Due 10/1/2022 on message board site Silicon Investor.
as of ET